1062. Analysis of Resistance to Oral Standard of Care Antibiotics for Urinary Tract Infections Caused By Escherichia coli and Staphylococcus saprophyticus Collected Worldwide between 2019-2020 Article Swipe
S J Ryan Arends
,
Deborah Butler
,
Nicole E. Scangarella-Oman
,
Lindsey Paustian
,
Jennifer M Streit
,
Rodrigo E. Mendes
·
YOU?
·
· 2021
· Open Access
·
· DOI: https://doi.org/10.1093/ofid/ofab466.1256
YOU?
·
· 2021
· Open Access
·
· DOI: https://doi.org/10.1093/ofid/ofab466.1256
Background Gepotidacin (GSK2140944) is a novel triazaacenaphthylene bacterial type II topoisomerase inhibitor under development for the treatment of gonorrhea and uncomplicated urinary tract infections (UTI). This study reports on the in vitro activity of gepotidacin and other oral antibiotics when tested against contemporary Escherichia coli and Staphylococcus saprophyticus clinical isolates collected from patients with UTIs for a gepotidacin uUTI global surveillance study as a part of the SENTRY Antimicrobial Surveillance Program. Methods A total of 3,562 E. coli and 344 S. saprophyticus isolates were collected between 2019 and 2020 from 92 medical centers located in 25 countries. Most isolates (68%) tested were cultured from urine specimens collected from patients seen in ambulatory, emergency, family practice, and outpatient medical services. Bacterial identifications were confirmed by MALDI-TOF. Isolates were tested for susceptibility by CLSI methods at a central laboratory (JMI Laboratories). MIC results for oral antibiotics licensed for the treatment of uUTI and drug-resistant subsets were interpreted per CLSI guidelines. Results Gepotidacin (MIC50/90, 2/2 mg/L) displayed good activity against 3,562 E. coli isolates, with 98.0% of all observed gepotidacin MICs ≤4 mg/L (Table). Susceptibility (S) rates for the other oral agents tested against these isolates were: amoxicillin-clavulanate (79.6% S), ampicillin (45.6% S), ciprofloxacin (72.5%S), fosfomycin (99.0% S), mecillinam (94.1%S), nitrofurantoin (97.3% S), and trimethoprim-sulfamethoxazole (68.2% S). When tested against the drug-resistant subsets, gepotidacin maintained similar MIC50/90 values (2/4 mg/L), except against isolates resistant to fosfomycin (2/8 mg/L). Against S. saprophyticus isolates, gepotidacin (MIC50/90, 0.06/0.12 mg/L) inhibited all isolates at ≤0.25 mg/L. Most oral agents showed S results of >97% against S. saprophyticus isolates, except for penicillin (3.5%S). Conclusion Gepotidacin demonstrated potent in vitro activity against contemporary E. coli and S. saprophyticus urine isolates. This activity was largely unaffected among isolates demonstrating drug-resistance to other oral standard of care antibiotics. Table Disclosures S J Ryan Arends, PhD, AbbVie (formerly Allergan) (Research Grant or Support)GlaxoSmithKline, LLC (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Nabriva Therapeutics (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Deborah Butler, n/a, GlaxoSmithKline, LLC (Employee) Nicole Scangarella-Oman, MS, GlaxoSmithKline, LLC (Employee) Lindsey Paustian, BS (ASCP), GlaxoSmithKline, LLC (Research Grant or Support) Jennifer M. Streit, BS, GlaxoSmithKline, LLC (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Rodrigo E. Mendes, PhD, AbbVie (Research Grant or Support)AbbVie (formerly Allergan) (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)ContraFect Corporation (Research Grant or Support)GlaxoSmithKline, LLC (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Nabriva Therapeutics (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support)
Related Topics
Concepts
Staphylococcus saprophyticus
Ciprofloxacin
Medicine
Nitrofurantoin
Microbiology
Fosfomycin
Sulfamethoxazole
Trimethoprim
Ampicillin
Antibiotics
Amoxicillin
Mecillinam
Staphylococcus
Escherichia coli
Staphylococcus aureus
Biology
Bacteria
Enterobacteriaceae
Biochemistry
Gene
Genetics
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1093/ofid/ofab466.1256
- OA Status
- gold
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4200627876
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4200627876Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1093/ofid/ofab466.1256Digital Object Identifier
- Title
-
1062. Analysis of Resistance to Oral Standard of Care Antibiotics for Urinary Tract Infections Caused By Escherichia coli and Staphylococcus saprophyticus Collected Worldwide between 2019-2020Work title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2021Year of publication
- Publication date
-
2021-11-01Full publication date if available
- Authors
-
S J Ryan Arends, Deborah Butler, Nicole E. Scangarella-Oman, Lindsey Paustian, Jennifer M Streit, Rodrigo E. MendesList of authors in order
- Landing page
-
https://doi.org/10.1093/ofid/ofab466.1256Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://doi.org/10.1093/ofid/ofab466.1256Direct OA link when available
- Concepts
-
Staphylococcus saprophyticus, Ciprofloxacin, Medicine, Nitrofurantoin, Microbiology, Fosfomycin, Sulfamethoxazole, Trimethoprim, Ampicillin, Antibiotics, Amoxicillin, Mecillinam, Staphylococcus, Escherichia coli, Staphylococcus aureus, Biology, Bacteria, Enterobacteriaceae, Biochemistry, Gene, GeneticsTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4200627876 |
|---|---|
| doi | https://doi.org/10.1093/ofid/ofab466.1256 |
| ids.doi | https://doi.org/10.1093/ofid/ofab466.1256 |
| ids.openalex | https://openalex.org/W4200627876 |
| fwci | 0.0 |
| type | article |
| title | 1062. Analysis of Resistance to Oral Standard of Care Antibiotics for Urinary Tract Infections Caused By Escherichia coli and Staphylococcus saprophyticus Collected Worldwide between 2019-2020 |
| biblio.issue | Supplement_1 |
| biblio.volume | 8 |
| biblio.last_page | S623 |
| biblio.first_page | S623 |
| topics[0].id | https://openalex.org/T11232 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9994999766349792 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2713 |
| topics[0].subfield.display_name | Epidemiology |
| topics[0].display_name | Urinary Tract Infections Management |
| topics[1].id | https://openalex.org/T10428 |
| topics[1].field.id | https://openalex.org/fields/24 |
| topics[1].field.display_name | Immunology and Microbiology |
| topics[1].score | 0.9779999852180481 |
| topics[1].domain.id | https://openalex.org/domains/1 |
| topics[1].domain.display_name | Life Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2404 |
| topics[1].subfield.display_name | Microbiology |
| topics[1].display_name | Reproductive tract infections research |
| topics[2].id | https://openalex.org/T12172 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.965399980545044 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2730 |
| topics[2].subfield.display_name | Oncology |
| topics[2].display_name | Neutropenia and Cancer Infections |
| is_xpac | False |
| apc_list.value | 3064 |
| apc_list.currency | USD |
| apc_list.value_usd | 3064 |
| apc_paid.value | 3064 |
| apc_paid.currency | USD |
| apc_paid.value_usd | 3064 |
| concepts[0].id | https://openalex.org/C2776580751 |
| concepts[0].level | 5 |
| concepts[0].score | 0.9234172701835632 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q1708986 |
| concepts[0].display_name | Staphylococcus saprophyticus |
| concepts[1].id | https://openalex.org/C2778512257 |
| concepts[1].level | 3 |
| concepts[1].score | 0.7189733982086182 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q256602 |
| concepts[1].display_name | Ciprofloxacin |
| concepts[2].id | https://openalex.org/C71924100 |
| concepts[2].level | 0 |
| concepts[2].score | 0.7186076641082764 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[2].display_name | Medicine |
| concepts[3].id | https://openalex.org/C2777629877 |
| concepts[3].level | 4 |
| concepts[3].score | 0.6873841285705566 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q422669 |
| concepts[3].display_name | Nitrofurantoin |
| concepts[4].id | https://openalex.org/C89423630 |
| concepts[4].level | 1 |
| concepts[4].score | 0.6274245381355286 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q7193 |
| concepts[4].display_name | Microbiology |
| concepts[5].id | https://openalex.org/C2778897966 |
| concepts[5].level | 3 |
| concepts[5].score | 0.6233835816383362 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q183554 |
| concepts[5].display_name | Fosfomycin |
| concepts[6].id | https://openalex.org/C2779425571 |
| concepts[6].level | 3 |
| concepts[6].score | 0.525290846824646 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q415843 |
| concepts[6].display_name | Sulfamethoxazole |
| concepts[7].id | https://openalex.org/C2780728791 |
| concepts[7].level | 3 |
| concepts[7].score | 0.5231515169143677 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q422665 |
| concepts[7].display_name | Trimethoprim |
| concepts[8].id | https://openalex.org/C2776021129 |
| concepts[8].level | 3 |
| concepts[8].score | 0.5220025181770325 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q244150 |
| concepts[8].display_name | Ampicillin |
| concepts[9].id | https://openalex.org/C501593827 |
| concepts[9].level | 2 |
| concepts[9].score | 0.5147607326507568 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q12187 |
| concepts[9].display_name | Antibiotics |
| concepts[10].id | https://openalex.org/C2779708577 |
| concepts[10].level | 3 |
| concepts[10].score | 0.4716868996620178 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q201928 |
| concepts[10].display_name | Amoxicillin |
| concepts[11].id | https://openalex.org/C2777894859 |
| concepts[11].level | 5 |
| concepts[11].score | 0.4150049090385437 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q13019044 |
| concepts[11].display_name | Mecillinam |
| concepts[12].id | https://openalex.org/C2779288629 |
| concepts[12].level | 4 |
| concepts[12].score | 0.30736231803894043 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q199695 |
| concepts[12].display_name | Staphylococcus |
| concepts[13].id | https://openalex.org/C547475151 |
| concepts[13].level | 3 |
| concepts[13].score | 0.2967063784599304 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q25419 |
| concepts[13].display_name | Escherichia coli |
| concepts[14].id | https://openalex.org/C2779489039 |
| concepts[14].level | 3 |
| concepts[14].score | 0.23961371183395386 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q188121 |
| concepts[14].display_name | Staphylococcus aureus |
| concepts[15].id | https://openalex.org/C86803240 |
| concepts[15].level | 0 |
| concepts[15].score | 0.17839190363883972 |
| concepts[15].wikidata | https://www.wikidata.org/wiki/Q420 |
| concepts[15].display_name | Biology |
| concepts[16].id | https://openalex.org/C523546767 |
| concepts[16].level | 2 |
| concepts[16].score | 0.10195112228393555 |
| concepts[16].wikidata | https://www.wikidata.org/wiki/Q10876 |
| concepts[16].display_name | Bacteria |
| concepts[17].id | https://openalex.org/C2778910516 |
| concepts[17].level | 4 |
| concepts[17].score | 0.09192872047424316 |
| concepts[17].wikidata | https://www.wikidata.org/wiki/Q380136 |
| concepts[17].display_name | Enterobacteriaceae |
| concepts[18].id | https://openalex.org/C55493867 |
| concepts[18].level | 1 |
| concepts[18].score | 0.0 |
| concepts[18].wikidata | https://www.wikidata.org/wiki/Q7094 |
| concepts[18].display_name | Biochemistry |
| concepts[19].id | https://openalex.org/C104317684 |
| concepts[19].level | 2 |
| concepts[19].score | 0.0 |
| concepts[19].wikidata | https://www.wikidata.org/wiki/Q7187 |
| concepts[19].display_name | Gene |
| concepts[20].id | https://openalex.org/C54355233 |
| concepts[20].level | 1 |
| concepts[20].score | 0.0 |
| concepts[20].wikidata | https://www.wikidata.org/wiki/Q7162 |
| concepts[20].display_name | Genetics |
| keywords[0].id | https://openalex.org/keywords/staphylococcus-saprophyticus |
| keywords[0].score | 0.9234172701835632 |
| keywords[0].display_name | Staphylococcus saprophyticus |
| keywords[1].id | https://openalex.org/keywords/ciprofloxacin |
| keywords[1].score | 0.7189733982086182 |
| keywords[1].display_name | Ciprofloxacin |
| keywords[2].id | https://openalex.org/keywords/medicine |
| keywords[2].score | 0.7186076641082764 |
| keywords[2].display_name | Medicine |
| keywords[3].id | https://openalex.org/keywords/nitrofurantoin |
| keywords[3].score | 0.6873841285705566 |
| keywords[3].display_name | Nitrofurantoin |
| keywords[4].id | https://openalex.org/keywords/microbiology |
| keywords[4].score | 0.6274245381355286 |
| keywords[4].display_name | Microbiology |
| keywords[5].id | https://openalex.org/keywords/fosfomycin |
| keywords[5].score | 0.6233835816383362 |
| keywords[5].display_name | Fosfomycin |
| keywords[6].id | https://openalex.org/keywords/sulfamethoxazole |
| keywords[6].score | 0.525290846824646 |
| keywords[6].display_name | Sulfamethoxazole |
| keywords[7].id | https://openalex.org/keywords/trimethoprim |
| keywords[7].score | 0.5231515169143677 |
| keywords[7].display_name | Trimethoprim |
| keywords[8].id | https://openalex.org/keywords/ampicillin |
| keywords[8].score | 0.5220025181770325 |
| keywords[8].display_name | Ampicillin |
| keywords[9].id | https://openalex.org/keywords/antibiotics |
| keywords[9].score | 0.5147607326507568 |
| keywords[9].display_name | Antibiotics |
| keywords[10].id | https://openalex.org/keywords/amoxicillin |
| keywords[10].score | 0.4716868996620178 |
| keywords[10].display_name | Amoxicillin |
| keywords[11].id | https://openalex.org/keywords/mecillinam |
| keywords[11].score | 0.4150049090385437 |
| keywords[11].display_name | Mecillinam |
| keywords[12].id | https://openalex.org/keywords/staphylococcus |
| keywords[12].score | 0.30736231803894043 |
| keywords[12].display_name | Staphylococcus |
| keywords[13].id | https://openalex.org/keywords/escherichia-coli |
| keywords[13].score | 0.2967063784599304 |
| keywords[13].display_name | Escherichia coli |
| keywords[14].id | https://openalex.org/keywords/staphylococcus-aureus |
| keywords[14].score | 0.23961371183395386 |
| keywords[14].display_name | Staphylococcus aureus |
| keywords[15].id | https://openalex.org/keywords/biology |
| keywords[15].score | 0.17839190363883972 |
| keywords[15].display_name | Biology |
| keywords[16].id | https://openalex.org/keywords/bacteria |
| keywords[16].score | 0.10195112228393555 |
| keywords[16].display_name | Bacteria |
| keywords[17].id | https://openalex.org/keywords/enterobacteriaceae |
| keywords[17].score | 0.09192872047424316 |
| keywords[17].display_name | Enterobacteriaceae |
| language | en |
| locations[0].id | doi:10.1093/ofid/ofab466.1256 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S2735126445 |
| locations[0].source.issn | 2328-8957 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 2328-8957 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | Open Forum Infectious Diseases |
| locations[0].source.host_organization | https://openalex.org/P4310311648 |
| locations[0].source.host_organization_name | Oxford University Press |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310311648 |
| locations[0].license | cc-by |
| locations[0].pdf_url | |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Open Forum Infectious Diseases |
| locations[0].landing_page_url | https://doi.org/10.1093/ofid/ofab466.1256 |
| locations[1].id | pmh:oai:pubmedcentral.nih.gov:8644303 |
| locations[1].is_oa | True |
| locations[1].source.id | https://openalex.org/S2764455111 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed Central |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | other-oa |
| locations[1].pdf_url | |
| locations[1].version | submittedVersion |
| locations[1].raw_type | Text |
| locations[1].license_id | https://openalex.org/licenses/other-oa |
| locations[1].is_accepted | False |
| locations[1].is_published | False |
| locations[1].raw_source_name | Open Forum Infect Dis |
| locations[1].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/8644303 |
| indexed_in | crossref, doaj |
| authorships[0].author.id | https://openalex.org/A5063276526 |
| authorships[0].author.orcid | https://orcid.org/0000-0001-5961-6238 |
| authorships[0].author.display_name | S J Ryan Arends |
| authorships[0].countries | US |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I4210121169 |
| authorships[0].affiliations[0].raw_affiliation_string | JMI Laboratories, North Liberty, Iowa |
| authorships[0].institutions[0].id | https://openalex.org/I4210121169 |
| authorships[0].institutions[0].ror | https://ror.org/02qv6pw23 |
| authorships[0].institutions[0].type | facility |
| authorships[0].institutions[0].lineage | https://openalex.org/I4210121169 |
| authorships[0].institutions[0].country_code | US |
| authorships[0].institutions[0].display_name | JMI Laboratories |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | S J Ryan Arends |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | JMI Laboratories, North Liberty, Iowa |
| authorships[1].author.id | https://openalex.org/A5043344284 |
| authorships[1].author.orcid | |
| authorships[1].author.display_name | Deborah Butler |
| authorships[1].countries | US |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I4210114143 |
| authorships[1].affiliations[0].raw_affiliation_string | GSK, Collegeville, Pennsylvania |
| authorships[1].institutions[0].id | https://openalex.org/I4210114143 |
| authorships[1].institutions[0].ror | https://ror.org/025vn3989 |
| authorships[1].institutions[0].type | company |
| authorships[1].institutions[0].lineage | https://openalex.org/I188950975, https://openalex.org/I4210114143 |
| authorships[1].institutions[0].country_code | US |
| authorships[1].institutions[0].display_name | GlaxoSmithKline (United States) |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Deborah Butler |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | GSK, Collegeville, Pennsylvania |
| authorships[2].author.id | https://openalex.org/A5084528882 |
| authorships[2].author.orcid | https://orcid.org/0000-0003-4211-8261 |
| authorships[2].author.display_name | Nicole E. Scangarella-Oman |
| authorships[2].countries | US |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I4210114143 |
| authorships[2].affiliations[0].raw_affiliation_string | GlaxoSmithKline Pharmaceuticals, Collegeville, Pennsylvania |
| authorships[2].institutions[0].id | https://openalex.org/I4210114143 |
| authorships[2].institutions[0].ror | https://ror.org/025vn3989 |
| authorships[2].institutions[0].type | company |
| authorships[2].institutions[0].lineage | https://openalex.org/I188950975, https://openalex.org/I4210114143 |
| authorships[2].institutions[0].country_code | US |
| authorships[2].institutions[0].display_name | GlaxoSmithKline (United States) |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Nicole Scangarella-Oman |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | GlaxoSmithKline Pharmaceuticals, Collegeville, Pennsylvania |
| authorships[3].author.id | https://openalex.org/A5033942179 |
| authorships[3].author.orcid | |
| authorships[3].author.display_name | Lindsey Paustian |
| authorships[3].countries | US |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I4210121169 |
| authorships[3].affiliations[0].raw_affiliation_string | JMI Laboratories, North Liberty, Iowa |
| authorships[3].institutions[0].id | https://openalex.org/I4210121169 |
| authorships[3].institutions[0].ror | https://ror.org/02qv6pw23 |
| authorships[3].institutions[0].type | facility |
| authorships[3].institutions[0].lineage | https://openalex.org/I4210121169 |
| authorships[3].institutions[0].country_code | US |
| authorships[3].institutions[0].display_name | JMI Laboratories |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Lindsey Paustian |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | JMI Laboratories, North Liberty, Iowa |
| authorships[4].author.id | https://openalex.org/A5014992940 |
| authorships[4].author.orcid | https://orcid.org/0000-0002-8419-6308 |
| authorships[4].author.display_name | Jennifer M Streit |
| authorships[4].countries | US |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I4210121169 |
| authorships[4].affiliations[0].raw_affiliation_string | JMI Laboratories, North Liberty, Iowa |
| authorships[4].institutions[0].id | https://openalex.org/I4210121169 |
| authorships[4].institutions[0].ror | https://ror.org/02qv6pw23 |
| authorships[4].institutions[0].type | facility |
| authorships[4].institutions[0].lineage | https://openalex.org/I4210121169 |
| authorships[4].institutions[0].country_code | US |
| authorships[4].institutions[0].display_name | JMI Laboratories |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Jennifer M Streit |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | JMI Laboratories, North Liberty, Iowa |
| authorships[5].author.id | https://openalex.org/A5041157580 |
| authorships[5].author.orcid | https://orcid.org/0000-0002-8648-1137 |
| authorships[5].author.display_name | Rodrigo E. Mendes |
| authorships[5].countries | US |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I4210121169 |
| authorships[5].affiliations[0].raw_affiliation_string | JMI Laboratories, North Liberty, Iowa |
| authorships[5].institutions[0].id | https://openalex.org/I4210121169 |
| authorships[5].institutions[0].ror | https://ror.org/02qv6pw23 |
| authorships[5].institutions[0].type | facility |
| authorships[5].institutions[0].lineage | https://openalex.org/I4210121169 |
| authorships[5].institutions[0].country_code | US |
| authorships[5].institutions[0].display_name | JMI Laboratories |
| authorships[5].author_position | last |
| authorships[5].raw_author_name | Rodrigo E Mendes |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | JMI Laboratories, North Liberty, Iowa |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doi.org/10.1093/ofid/ofab466.1256 |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2021-12-31T00:00:00 |
| display_name | 1062. Analysis of Resistance to Oral Standard of Care Antibiotics for Urinary Tract Infections Caused By Escherichia coli and Staphylococcus saprophyticus Collected Worldwide between 2019-2020 |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T11232 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9994999766349792 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2713 |
| primary_topic.subfield.display_name | Epidemiology |
| primary_topic.display_name | Urinary Tract Infections Management |
| related_works | https://openalex.org/W4200140193, https://openalex.org/W3081741700, https://openalex.org/W4321078077, https://openalex.org/W3040034976, https://openalex.org/W2913022205, https://openalex.org/W4244370164, https://openalex.org/W2974072034, https://openalex.org/W3169590978, https://openalex.org/W4220968898, https://openalex.org/W2762426119 |
| cited_by_count | 0 |
| locations_count | 2 |
| best_oa_location.id | doi:10.1093/ofid/ofab466.1256 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S2735126445 |
| best_oa_location.source.issn | 2328-8957 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 2328-8957 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | Open Forum Infectious Diseases |
| best_oa_location.source.host_organization | https://openalex.org/P4310311648 |
| best_oa_location.source.host_organization_name | Oxford University Press |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310311648 |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Open Forum Infectious Diseases |
| best_oa_location.landing_page_url | https://doi.org/10.1093/ofid/ofab466.1256 |
| primary_location.id | doi:10.1093/ofid/ofab466.1256 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S2735126445 |
| primary_location.source.issn | 2328-8957 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 2328-8957 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | Open Forum Infectious Diseases |
| primary_location.source.host_organization | https://openalex.org/P4310311648 |
| primary_location.source.host_organization_name | Oxford University Press |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310311648 |
| primary_location.license | cc-by |
| primary_location.pdf_url | |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Open Forum Infectious Diseases |
| primary_location.landing_page_url | https://doi.org/10.1093/ofid/ofab466.1256 |
| publication_date | 2021-11-01 |
| publication_year | 2021 |
| referenced_works_count | 0 |
| abstract_inverted_index.A | 73 |
| abstract_inverted_index.J | 301 |
| abstract_inverted_index.S | 254, 300 |
| abstract_inverted_index.a | 5, 57, 64, 135 |
| abstract_inverted_index.25 | 96 |
| abstract_inverted_index.92 | 91 |
| abstract_inverted_index.BS | 347 |
| abstract_inverted_index.E. | 77, 169, 275, 381 |
| abstract_inverted_index.II | 10 |
| abstract_inverted_index.M. | 356 |
| abstract_inverted_index.S. | 81, 237, 259, 278 |
| abstract_inverted_index.as | 63 |
| abstract_inverted_index.at | 134, 247 |
| abstract_inverted_index.by | 124, 131 |
| abstract_inverted_index.in | 31, 95, 111, 270 |
| abstract_inverted_index.is | 4 |
| abstract_inverted_index.of | 18, 34, 66, 75, 149, 174, 256, 295 |
| abstract_inverted_index.on | 29 |
| abstract_inverted_index.or | 310, 315, 321, 326, 331, 353, 363, 369, 373, 378, 387, 393, 398, 404, 409, 414, 420, 426, 431, 436, 440, 445 |
| abstract_inverted_index.to | 232, 291 |
| abstract_inverted_index.(S) | 183 |
| abstract_inverted_index.2/2 | 162 |
| abstract_inverted_index.344 | 80 |
| abstract_inverted_index.BS, | 358 |
| abstract_inverted_index.LLC | 312, 318, 337, 343, 350, 360, 366, 411, 423 |
| abstract_inverted_index.MIC | 140 |
| abstract_inverted_index.MS, | 341 |
| abstract_inverted_index.S), | 197, 200, 205, 210 |
| abstract_inverted_index.S). | 214 |
| abstract_inverted_index.USA | 400 |
| abstract_inverted_index.all | 175, 245 |
| abstract_inverted_index.and | 20, 36, 46, 79, 88, 116, 151, 211, 277 |
| abstract_inverted_index.for | 15, 56, 129, 142, 146, 185, 263 |
| abstract_inverted_index.per | 156 |
| abstract_inverted_index.the | 16, 30, 67, 147, 186, 218 |
| abstract_inverted_index.was | 284 |
| abstract_inverted_index.(2/4 | 226 |
| abstract_inverted_index.(2/8 | 234 |
| abstract_inverted_index.(JMI | 138 |
| abstract_inverted_index.2019 | 87 |
| abstract_inverted_index.2020 | 89 |
| abstract_inverted_index.CLSI | 132, 157 |
| abstract_inverted_index.Inc. | 401, 417, 433 |
| abstract_inverted_index.MICs | 178 |
| abstract_inverted_index.Most | 98, 250 |
| abstract_inverted_index.PhD, | 304, 383 |
| abstract_inverted_index.Ryan | 302 |
| abstract_inverted_index.This | 26, 282 |
| abstract_inverted_index.UTIs | 55 |
| abstract_inverted_index.When | 215 |
| abstract_inverted_index.care | 296 |
| abstract_inverted_index.coli | 45, 78, 170, 276 |
| abstract_inverted_index.from | 52, 90, 104, 108 |
| abstract_inverted_index.good | 165 |
| abstract_inverted_index.mg/L | 180 |
| abstract_inverted_index.n/a, | 335 |
| abstract_inverted_index.oral | 38, 143, 188, 251, 293 |
| abstract_inverted_index.part | 65 |
| abstract_inverted_index.seen | 110 |
| abstract_inverted_index.type | 9 |
| abstract_inverted_index.uUTI | 59, 150 |
| abstract_inverted_index.were | 84, 102, 122, 127, 154 |
| abstract_inverted_index.when | 40 |
| abstract_inverted_index.with | 54, 172 |
| abstract_inverted_index.≤4 | 179 |
| abstract_inverted_index.(68%) | 100 |
| abstract_inverted_index.3,562 | 76, 168 |
| abstract_inverted_index.98.0% | 173 |
| abstract_inverted_index.Grant | 309, 314, 320, 325, 330, 352, 362, 368, 372, 377, 386, 392, 397, 403, 408, 413, 419, 425, 430, 435, 439, 444 |
| abstract_inverted_index.Table | 298 |
| abstract_inverted_index.among | 287 |
| abstract_inverted_index.mg/L) | 163, 243 |
| abstract_inverted_index.mg/L. | 249 |
| abstract_inverted_index.novel | 6 |
| abstract_inverted_index.other | 37, 187, 292 |
| abstract_inverted_index.rates | 184 |
| abstract_inverted_index.study | 27, 62 |
| abstract_inverted_index.these | 192 |
| abstract_inverted_index.total | 74 |
| abstract_inverted_index.tract | 23 |
| abstract_inverted_index.under | 13 |
| abstract_inverted_index.urine | 105, 280 |
| abstract_inverted_index.vitro | 32, 271 |
| abstract_inverted_index.were: | 194 |
| abstract_inverted_index.(45.6% | 199 |
| abstract_inverted_index.(68.2% | 213 |
| abstract_inverted_index.(79.6% | 196 |
| abstract_inverted_index.(97.3% | 209 |
| abstract_inverted_index.(99.0% | 204 |
| abstract_inverted_index.(UTI). | 25 |
| abstract_inverted_index.AbbVie | 305, 384 |
| abstract_inverted_index.Nicole | 339 |
| abstract_inverted_index.SENTRY | 68 |
| abstract_inverted_index.agents | 189, 252 |
| abstract_inverted_index.except | 228, 262 |
| abstract_inverted_index.family | 114 |
| abstract_inverted_index.global | 60 |
| abstract_inverted_index.mg/L), | 227 |
| abstract_inverted_index.mg/L). | 235 |
| abstract_inverted_index.potent | 269 |
| abstract_inverted_index.showed | 253 |
| abstract_inverted_index.tested | 41, 101, 128, 190, 216 |
| abstract_inverted_index.values | 225 |
| abstract_inverted_index.(ASCP), | 348 |
| abstract_inverted_index.Against | 236 |
| abstract_inverted_index.Arends, | 303 |
| abstract_inverted_index.Butler, | 334 |
| abstract_inverted_index.Deborah | 333 |
| abstract_inverted_index.Lindsey | 345 |
| abstract_inverted_index.Mendes, | 382 |
| abstract_inverted_index.Methods | 72 |
| abstract_inverted_index.Results | 159 |
| abstract_inverted_index.Rodrigo | 380 |
| abstract_inverted_index.Streit, | 357 |
| abstract_inverted_index.against | 42, 167, 191, 217, 229, 258, 273 |
| abstract_inverted_index.between | 86 |
| abstract_inverted_index.centers | 93 |
| abstract_inverted_index.central | 136 |
| abstract_inverted_index.largely | 285 |
| abstract_inverted_index.located | 94 |
| abstract_inverted_index.medical | 92, 118 |
| abstract_inverted_index.methods | 133 |
| abstract_inverted_index.reports | 28 |
| abstract_inverted_index.results | 141, 255 |
| abstract_inverted_index.similar | 223 |
| abstract_inverted_index.subsets | 153 |
| abstract_inverted_index.urinary | 22 |
| abstract_inverted_index.≤0.25 | 248 |
| abstract_inverted_index.(3.5%S). | 265 |
| abstract_inverted_index.(Table). | 181 |
| abstract_inverted_index.Abstract | 0 |
| abstract_inverted_index.Isolates | 126 |
| abstract_inverted_index.Jennifer | 355 |
| abstract_inverted_index.MIC50/90 | 224 |
| abstract_inverted_index.Program. | 71 |
| abstract_inverted_index.Support) | 332, 354, 379, 446 |
| abstract_inverted_index.activity | 33, 166, 272, 283 |
| abstract_inverted_index.clinical | 49 |
| abstract_inverted_index.cultured | 103 |
| abstract_inverted_index.isolates | 50, 83, 99, 193, 230, 246, 288 |
| abstract_inverted_index.licensed | 145 |
| abstract_inverted_index.observed | 176 |
| abstract_inverted_index.patients | 53, 109 |
| abstract_inverted_index.standard | 294 |
| abstract_inverted_index.subsets, | 220 |
| abstract_inverted_index.(72.5%S), | 202 |
| abstract_inverted_index.(94.1%S), | 207 |
| abstract_inverted_index.(Research | 308, 313, 319, 324, 329, 351, 361, 367, 371, 376, 385, 391, 396, 402, 407, 412, 418, 424, 429, 434, 438, 443 |
| abstract_inverted_index.(formerly | 306, 389 |
| abstract_inverted_index.0.06/0.12 | 242 |
| abstract_inverted_index.Allergan) | 307, 390 |
| abstract_inverted_index.Bacterial | 120 |
| abstract_inverted_index.Paustian, | 346 |
| abstract_inverted_index.bacterial | 8 |
| abstract_inverted_index.collected | 51, 85, 107 |
| abstract_inverted_index.confirmed | 123 |
| abstract_inverted_index.displayed | 164 |
| abstract_inverted_index.gonorrhea | 19 |
| abstract_inverted_index.inhibited | 244 |
| abstract_inverted_index.inhibitor | 12 |
| abstract_inverted_index.isolates, | 171, 239, 261 |
| abstract_inverted_index.isolates. | 281 |
| abstract_inverted_index.practice, | 115 |
| abstract_inverted_index.resistant | 231 |
| abstract_inverted_index.services. | 119 |
| abstract_inverted_index.specimens | 106 |
| abstract_inverted_index.treatment | 17, 148 |
| abstract_inverted_index.(Employee) | 338, 344 |
| abstract_inverted_index.(MIC50/90, | 161, 241 |
| abstract_inverted_index.Background | 1 |
| abstract_inverted_index.Conclusion | 266 |
| abstract_inverted_index.MALDI-TOF. | 125 |
| abstract_inverted_index.ampicillin | 198 |
| abstract_inverted_index.countries. | 97 |
| abstract_inverted_index.emergency, | 113 |
| abstract_inverted_index.fosfomycin | 203, 233 |
| abstract_inverted_index.infections | 24 |
| abstract_inverted_index.laboratory | 137 |
| abstract_inverted_index.maintained | 222 |
| abstract_inverted_index.mecillinam | 206 |
| abstract_inverted_index.outpatient | 117 |
| abstract_inverted_index.penicillin | 264 |
| abstract_inverted_index.unaffected | 286 |
| abstract_inverted_index.>97% | 257 |
| abstract_inverted_index.Corporation | 406 |
| abstract_inverted_index.Disclosures | 299 |
| abstract_inverted_index.Escherichia | 44 |
| abstract_inverted_index.Gepotidacin | 2, 160, 267 |
| abstract_inverted_index.ambulatory, | 112 |
| abstract_inverted_index.antibiotics | 39, 144 |
| abstract_inverted_index.development | 14 |
| abstract_inverted_index.gepotidacin | 35, 58, 177, 221, 240 |
| abstract_inverted_index.guidelines. | 158 |
| abstract_inverted_index.interpreted | 155 |
| abstract_inverted_index.(GSK2140944) | 3 |
| abstract_inverted_index.Surveillance | 70 |
| abstract_inverted_index.Therapeutics | 323, 328, 375, 395, 428, 442 |
| abstract_inverted_index.antibiotics. | 297 |
| abstract_inverted_index.contemporary | 43, 274 |
| abstract_inverted_index.demonstrated | 268 |
| abstract_inverted_index.surveillance | 61 |
| abstract_inverted_index.Antimicrobial | 69 |
| abstract_inverted_index.Support)Cipla | 394, 399 |
| abstract_inverted_index.Support)Spero | 327, 374, 441 |
| abstract_inverted_index.Therapeutics, | 317, 365, 416, 422 |
| abstract_inverted_index.ciprofloxacin | 201 |
| abstract_inverted_index.demonstrating | 289 |
| abstract_inverted_index.saprophyticus | 48, 82, 238, 260, 279 |
| abstract_inverted_index.topoisomerase | 11 |
| abstract_inverted_index.uncomplicated | 21 |
| abstract_inverted_index.Laboratories). | 139 |
| abstract_inverted_index.Staphylococcus | 47 |
| abstract_inverted_index.Support)AbbVie | 388 |
| abstract_inverted_index.Susceptibility | 182 |
| abstract_inverted_index.drug-resistant | 152, 219 |
| abstract_inverted_index.nitrofurantoin | 208 |
| abstract_inverted_index.susceptibility | 130 |
| abstract_inverted_index.Support)Melinta | 316, 364, 415, 421 |
| abstract_inverted_index.Support)Nabriva | 322, 427 |
| abstract_inverted_index.Support)Pfizer, | 432 |
| abstract_inverted_index.drug-resistance | 290 |
| abstract_inverted_index.identifications | 121 |
| abstract_inverted_index.GlaxoSmithKline, | 336, 342, 349, 359 |
| abstract_inverted_index.Support)Shionogi | 370, 437 |
| abstract_inverted_index.Scangarella-Oman, | 340 |
| abstract_inverted_index.Support)ContraFect | 405 |
| abstract_inverted_index.triazaacenaphthylene | 7 |
| abstract_inverted_index.amoxicillin-clavulanate | 195 |
| abstract_inverted_index.Support)GlaxoSmithKline, | 311, 410 |
| abstract_inverted_index.trimethoprim-sulfamethoxazole | 212 |
| cited_by_percentile_year | |
| countries_distinct_count | 1 |
| institutions_distinct_count | 6 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.5099999904632568 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.25957988 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |